Here are the 424B prospectus supplements from Solid Biosciences Inc. (SLDB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SLDB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLDB filings page.
Solid Biosciences Inc. is registering an at-the-market offering of up to $200,000,000 of common stock under an amended sales agreement with Jefferies LLC, which will act as sales agent and receive up to 3.0% of the gross sales price as commission. Sales may be made from time to time through The Nasdaq Global Select Market or other permitted methods deemed an at-the-market offering under Rule 415(a)(4). Shares outstanding were 105,125,366 as of June 30, 2026, and an illustrative dilution calculation using a price of $8.73 per share shows net tangible book value per share rising from $3.56 to $4.43, with dilution of $4.30 per share to new investors if the full $200.0 million is sold. The company plans to use any net proceeds for general corporate purposes, including research and development, preclinical and clinical work, potential acquisitions or in-licenses, debt repayment or refinancing, working capital and capital expenditures.
SLDB files a prospectus supplement updating its list of selling stockholders. The supplement states the aggregate number of shares registered remains the same and replaces the prior selling‑stockholder table with updated holdings as of May 15, 2026. The supplement cites 98,449,606 shares outstanding as of May 15, 2026 used to calculate percentages.
The table shows multiple large holders with updated "Number of Shares Being Offered" and resulting post‑offering percentages; the prospectus supplement is to be read together with the March 31, 2026 prospectus.